Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... medicine company prepares for commercial launch of first ... ... AssureRx, a personalized medicine,company, announced that Al Lucas has joined ... responsible for developing the marketing,plan and initial launch strategy, building the ...
... VEENENDAAL, The Netherlands, April 28 , ... HDR/PDR Brachytherapy Represents the,Next Generation in ... Nucletron, a knowledge-based leader in radiation ... Brachy*, a comprehensive,volume-based treatment planning system ...
... cellular energy, NEW YORK, April 28 Ever been ... not catch up? That,s how Holly Jacobson, a nurse,in Clermont, ... to be,exhausted -- five boys under the age of nine. ... sixth son, and she began experiencing palpitations,breathlessness and fatigue whenever ...
Cached Biology Technology:AssureRx Adds VP of Sales and Marketing 2Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment 2D-Ribose Helps Energy-Starved Hearts 2
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological havoc, ... global scales. But new research from Brown University shows ... life at the time of an impact. , A ... found fragments of leaves and preserved organic compounds lodged ... Argentina. The material could provide a snapshot of environmental ...
(Date:4/17/2014)... the most densely forested and most densely populated quadrant ... human needs, values and practices. Disturbances associated with those ... and development, have set the stage for management issues ... reports. , The report Five anthropogenic factors that ... the Northern United States was published recently ...
(Date:4/17/2014)... peptide inhibits RSV infection , Respiratory syncytial ... respiratory tract infections, generating life-threating illness in very ... therapies are limited. RSV enters host cells through ... six-helix fusogenic bundle. Small interfering peptides that prevent ... these peptides are highly susceptible to degradation. In ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... most farmers consider viruses and fungi potential threats to ... to extreme conditions, according to a Penn State virologist. ... plants is a key to sustainable agriculture that can ... possible conflicts over scare resources, said Marilyn Roossinck, professor ...
... now the first and only place in Europe where pathogens ... those responsible for AIDS, Hepatitis and some types of flu ... synchrotron light. This special light allows scientists to study virus ... extends that capability to many viruses that have a major ...
... cells more economical, engineers want a fast and efficient iron-based ... 17 at Nature Chemistry , researchers report such a ... directly to electricity. The result moves chemists and engineers one ... with today,s fuel cells is that the platinum they use ...
Cached Biology News:Microbes team up to boost plants' stress tolerance 2Diamond sheds light on basic building blocks of life 2Diamond sheds light on basic building blocks of life 3Synthetic molecule first electricity-making catalyst to use iron to split hydrogen gas 2Synthetic molecule first electricity-making catalyst to use iron to split hydrogen gas 3
... uptake of long double stranded RNA (dsRNA) ... in a diverse group of organisms as ... interference leads to the inhibition of protein ... the target messenger RNA (mRNA). Attempts to ...
... exact mass measurements in an easy-to-use ... time-of-flight mass spectrometer (ESI-oa-TOF) concentrates the ... a format, which fits on your ... resolution exceeding 10,000 FWHM and mass ...
... TSQ Quantum Ultra defines a new standard ... analysis. It features the revolutionary Ion ... titanium skimmer with superior skimming and larger ... Its redesigned ion transfer tube lens with ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
Biology Products: